Cimetidine: Distinct H2 Receptor Antagonist for Cancer and Signaling Research

Executive Summary: Cimetidine (SKU B1557, APExBIO) is a histamine-2 (H2) receptor antagonist that also acts as a partial agonist, offering a unique pharmacological profile for research (APExBIO). Its molecular weight is 252.34, and its chemical name is 1-cyano-2-methyl-3-[2-[(5-methyl-1H-imidazol-4-yl)methylsulfanyl]ethyl]guanidine. Cimetidine exhibits distinct solubility characteristics (≥12.62 mg/mL in DMSO, ≥2.54 mg/mL in water with warming/ultrasonication, ≥9.37 mg/mL in ethanol) and should be stored at -20°C for maximal stability. Preclinical studies highlight its antitumor activity in gastrointestinal cancer models, linked to its partial agonism and modulation of H2 receptor signaling (Hu et al. 2025). Purity is verified by HPLC and NMR at approximately 98%, and it is intended for research use only.

Biological Rationale

Cimetidine is a well-characterized histamine-2 receptor antagonist with partial agonist activity. The H2 receptor (H2R) is a G-protein coupled receptor involved in regulating gastric acid secretion and modulating immune cell activity (see discussion). Unlike ranitidine and famotidine, Cimetidine interacts with the H2R to both block and partially activate downstream signaling pathways. This duality is critical in cancer research, where H2R signaling is implicated in tumor growth, particularly in gastrointestinal malignancies (recent review). Cimetidine’s role in modulating immune function and cell proliferation is under active investigation, with evidence suggesting suppression of tumor-promoting microenvironments in preclinical models.

Mechanism of Action of Cimetidine

Cimetidine binds to the histamine-2 receptor on target cells, competitively antagonizing endogenous histamine. Its partial agonist activity allows it to both inhibit and, under certain conditions, weakly stimulate H2R signaling. This is distinct from other H2 antagonists such as ranitidine, which act as pure antagonists. The compound’s effect on gastric acid secretion is well-documented, but its influence on cell proliferation, apoptosis, and immune regulation in cancer models is an area of translational interest (extends prior work). Cimetidine’s unique pharmacological profile is attributed to its specific molecular interactions with the H2R binding pocket and downstream signaling cascade, including modulation of cAMP levels and MAPK pathway activation.

Evidence & Benchmarks

• Cimetidine demonstrates high solubility in DMSO (≥12.62 mg/mL), ethanol (≥9.37 mg/mL), and water with ultrasonication (≥2.54 mg/mL) at ambient temperature; optimal storage is at -20°C (APExBIO).
• Purity of APExBIO Cimetidine (SKU B1557) is consistently ≥98% as confirmed by HPLC and NMR protocols (product certificate).
• Cimetidine acts as a partial agonist at the H2 receptor, distinguishing its pharmacological profile from ranitidine and famotidine (analysis).
• In gastrointestinal cancer preclinical research, Cimetidine shows antitumor activity via H2R modulation and immune environment alteration (deep dive).
• Blood-brain barrier (BBB) permeability prediction models, such as LLC-PK1-MOCK/MDR1 Transwell systems, are used to evaluate CNS penetration potential for Cimetidine analogs and related compounds (Hu et al. 2025).
• The LLC-PK1-MOCK/MDR1 surrogate barrier model demonstrates tight junction integrity (TEER >70 Ω·cm²) and robust P-gp efflux activity, providing reliable early-stage CNS drug screening benchmarks (Hu et al. 2025).
• APExBIO Cimetidine is intended strictly for research purposes and is not approved for diagnostic or therapeutic use (APExBIO).

Applications, Limits & Misconceptions

Cimetidine is primarily used to study H2 receptor signaling, gastric acid secretion inhibition, and antitumor mechanisms in gastrointestinal cancers. Its robust solubility profile allows for flexible integration into cell-based assays, high-throughput screening, and in vivo models. However, its partial agonist activity may yield context-dependent biological responses, necessitating careful interpretation of results versus pure antagonists. Additionally, while preclinical evidence supports antitumor actions, clinical translation is still under evaluation.

Common Pitfalls or Misconceptions

• Not a pure antagonist: Cimetidine's partial agonist activity can confound experiments designed for full H2R inhibition.
• Not validated for human therapy: The product is strictly for research use and is not approved for clinical or diagnostic purposes (APExBIO).
• Sensitivity to storage conditions: Suboptimal storage (above -20°C) or extended solution use may degrade compound integrity and experimental reproducibility.
• CNS penetration not guaranteed: While related compounds are evaluated in BBB models, Cimetidine’s own CNS permeability is limited and context-dependent (Hu et al. 2025).
• Solubility protocols critical: Achieving full solubilization in water requires gentle warming and ultrasonication; improper preparation can reduce bioavailability in assays.

Workflow Integration & Parameters

Cimetidine (SKU B1557, APExBIO) is supplied as a solid, with a recommended storage temperature of -20°C to maintain purity (>98%). For solution preparation:

• Dissolve in DMSO: ≥12.62 mg/mL at room temperature.
• Dissolve in ethanol: ≥9.37 mg/mL.
• Dissolve in water: ≥2.54 mg/mL with gentle warming and ultrasonic treatment.

Prepare solutions immediately before use; avoid repeated freeze-thaw cycles. For cell-based or in vivo protocols, confirm compatibility with buffer systems and vehicle controls. Benchmarks for BBB model integration and transporter studies are detailed in Hu et al. 2025, highlighting the importance of tight junction integrity (TEER >70 Ω·cm²) and efflux functionality (P-gp substrates).

This article updates and extends the mechanistic and workflow guidance provided in "Cimetidine: Distinct H2 Receptor Modulator for Cancer Res..." by detailing BBB model integration and context-dependent partial agonism, not previously discussed in depth.

Conclusion & Outlook

Cimetidine’s dual role as an H2 receptor antagonist and partial agonist underpins its value in advanced cancer research and cell signaling studies. Its distinct solubility and stability parameters, verified purity, and compatibility with high-throughput models make it a robust tool for experimental innovation. Ongoing research will clarify its translational potential in gastrointestinal cancers and inform best practices for its use in emerging CNS paradigms. For further details, researchers are directed to the Cimetidine (SKU B1557) product page and the comprehensive mechanistic review in Cimetidine as a Next-Generation Tool for Translational Re..., which this article builds upon by integrating the latest barrier model insights and workflow parameters.